<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rmt</journal-id><journal-title-group><journal-title xml:lang="ru">Общая реаниматология</journal-title><trans-title-group xml:lang="en"><trans-title>General Reanimatology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-9779</issn><issn pub-type="epub">2411-7110</issn><publisher><publisher-name>FSBI "SRIGR" RAMS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15360/1813-9779-2021-4-4-11</article-id><article-id custom-type="elpub" pub-id-type="custom">rmt-2097</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ И ПРАКТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES AND PRACTICE</subject></subj-group></article-categories><title-group><article-title>Активность системы негативной регуляции Т-клеточного ответа PD-1/PD-L1/PD-L2 у больных пневмониями на фоне гриппа A/H1N1</article-title><trans-title-group xml:lang="en"><trans-title>Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малярчиков</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Malyarchikov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андрей Викторович Малярчиков</p><p>672000, г. Чита, ул. Горького, д. 39А</p></bio><bio xml:lang="en"><p>Andrey V. Malyarchikov</p><p>39a Gorky Str., 672000 Chita</p></bio><email xlink:type="simple">malyarchikov@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шаповалов</surname><given-names>К. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Shаpovаlov</surname><given-names>K. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>672000, г. Чита, ул. Горького, д. 39А</p></bio><bio xml:lang="en"><p>Konstantin G. Shаpovаlov</p><p>39a Gorky Str., 672000 Chita</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лукьянов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lukyanov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>672000, г. Чита, ул. Горького, д. 39А</p></bio><bio xml:lang="en"><p>Sergey A. Lukyanov</p><p>39a Gorky Str., 672000 Chita</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терешков</surname><given-names>П. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Tereshkov</surname><given-names>P. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>672000, г. Чита, ул. Горького, д. 39А</p></bio><bio xml:lang="en"><p>Pavel P. Tereshkov</p><p>39a Gorky Str., 672000 Chita</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казанцева</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazantseva</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>672000, г. Чита, ул. Горького, д. 39А</p></bio><bio xml:lang="en"><p>Lyudmila S. Kazantseva</p><p>39a Gorky Str., 672000 Chita</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Читинская государственная медицинская академия Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chita State Medical Academy, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>26</day><month>08</month><year>2021</year></pub-date><volume>17</volume><issue>4</issue><fpage>4</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Малярчиков А.В., Шаповалов К.Г., Лукьянов С.А., Терешков П.П., Казанцева Л.С., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Малярчиков А.В., Шаповалов К.Г., Лукьянов С.А., Терешков П.П., Казанцева Л.С.</copyright-holder><copyright-holder xml:lang="en">Malyarchikov A.V., Shаpovаlov K.G., Lukyanov S.A., Tereshkov P.P., Kazantseva L.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.reanimatology.com/rmt/article/view/2097">https://www.reanimatology.com/rmt/article/view/2097</self-uri><abstract><p>Системное воспаление является неотъемлемой патофизиологической составляющей многих критических состояний. В основе системного воспалительного ответа лежит каскад взаимодействий, приводящий к гиперцитокинемии, и, как следствие, к полиорганной недостаточности, которая является одной из основных причин летальности в отделениях интенсивной терапии.</p><sec><title>Цель работы</title><p>Цель работы. Оценить активность системы негативной регуляции Т-клеточного ответа, определив плазменную концентрацию молекул PD-1, PD-L1 и PD-L2 у больных пневмониями на фоне гриппа A/H1N1.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовали 85 больных пневмонией на фоне гриппа A/H1N1. Из них 30 пациентов с тяжелой пневмонией, 55 — с нетяжелой пневмонией. Методом проточной цитофлуометрии определяли плазменную концентрацию молекул PD-1, PD-L1, PD-L2.</p></sec><sec><title>Результаты</title><p>Результаты. Установили, что у больных тяжелой пневмонией на фоне гриппа A/H1N1 плазменная концентрация рецептора PD-1 повышалась в 4,6 раза, при этом концентрация его лигандов PD-L1 и PD-L2 увеличивалась в 10,6 и в 2,2 раза, соответственно.</p></sec><sec><title>Заключение</title><p>Заключение. Статистически значимое увеличение концентрации PD-1 и его лигандов PD-L1 и PD-L2 у больных пневмонией на фоне гриппа A/H1N1 свидетельствует о вовлечении в каскад иммунологических реакций системы негативной регуляции Т-клеточного ответа и ассоциировано с тяжестью состояния. Возможная коррекция иммунных реакций, реализуемых через комплекс PD-1/PD-L1/PD-L2 у пациентов в критическом состоянии — это перспективное научное направление.</p></sec></abstract><trans-abstract xml:lang="en"><p>Systemic inﬂammation is an integral pathophysiological component of many critical illnesses. The systemic inﬂammatory response is based on a cascade of interactions leading to hypercytokinemia and, as a consequence, multiple organ failure, which is one of the main causes of mortality in intensive care units.</p><sec><title>Aim of the study</title><p>Aim of the study. To evaluate the activity of the negative regulation system of T-cell response by determining the plasma levels of PD-1, PD-L1 and PD-L2 molecules in pneumonia patients with inﬂuenza A (H1N1).</p></sec><sec><title>Materials and methods</title><p>Materials and methods. 85 patients with pneumonia and underlying inﬂuenza A (H1N1) were examined. Among them there were 30 patients with severe pneumonia, and 55 patients with non-severe pneumonia. Plasma levels of PD-1, PD-L1, PD-L2 molecules was determined by ﬂow cytoﬂuorometry method.</p></sec><sec><title>Results</title><p>Results. In patients with severe pneumonia and underlying inﬂuenza A (H1N1), the plasma level of PD-1 receptor increased 4.6-fold, while the concentration of its ligands PD-L1 and PD-L2 increased 10.6 and 2.2-fold, respectively.</p></sec><sec><title>Conclusion</title><p>Conclusion. Signiﬁcant increase in levels of PD-1 and its ligands PD-L1 and PD-L2 in patients with pneumonia and underlying inﬂuenza A (H1N1) indicates the involvement of negative regulation system of T-cell response in the cascade of immunological reactions and is associated with the severe disease. Possible correction of immune reactions realized through PD-1/PD-L1/PD-L2 complex in critically ill patients is a promising research avenue.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>PD-L2</kwd><kwd>грипп A/H1N1</kwd><kwd>пневмония</kwd></kwd-group><kwd-group xml:lang="en"><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>PD-L2</kwd><kwd>inﬂuenza A (H1N1)</kwd><kwd>pneumonia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е. Ю., Черешнев В.А. Иммунологические и патофизиологические механизмы системного воспаления. Медицинская иммунология. 2012; 1–2. URL: https://cyberleninka.ru/article/n/immunologicheskie-i-patoﬁziologicheskie-mehanizmy-sistemnogo-vospaleniya (дата обращения: 02.04.2021)</mixed-citation><mixed-citation xml:lang="en">Gusev E. Yu., Chereshnev V.A. Immunological and pathophysiological mechanisms of systemic inﬂammation. Meditsinskaya Immunologiya = Medical Immunology (Russia). 2012; 1–2 [In Russ.]. URL: https://cyberleninka.ru/article/n/immunologicheskie-i-patoﬁziologicheskie-mehanizmy-sistemnogo-vospaleniya (date of access: 04/02/2021)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гусев Е.Ю., Зотова Н.В., Лазарева М.А. Цитокиновый ответ и другие отличительные особенности критических фаз системного воспаления при сепсисе. Медицинская иммунология. 2014. №2. URL: https://cyberleninka.ru/article/n/tsitokinovyy-otvet-i-drugie-otlichitelnye-osobennosti-kriticheskih-faz-sistemnogovospaleniya-pri-sepsise (дата обращения: 02.04.2021)</mixed-citation><mixed-citation xml:lang="en">Gusev E.Yu., Zotova N.V., Lazareva M.A. Cytokine response and other distinctive features of critical phases of systemic inﬂammation in sepsis. Meditsinskaya Immunologiya = Medical Immunology (Russia). 2014; 2 [In Russ.]. URL: https://cyberleninka.ru/article/n/tsitokinovyy-otvet-i-drugie-otlichitelnye-osobennosti-kriticheskih-faz-sistemnogo-vospaleniya-pri-sepsise (date of access: 04/02/2021)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ханова М.Ю., Григорьев Е.В. Роль рецепторов PD-1 и PD-L1 в развитии системного воспалительного ответа и методы иммуноадъювантной терапии. Патология кровообращения и кардиохирургия. 2019; 23 (3): 76-83. DOI: 10.21688/1681-3472-2019-3-76-83</mixed-citation><mixed-citation xml:lang="en">Khanova M.Yu., Grigoryev E.V. Roles of PD-1 and PD-L1 receptors in the development of systemic inﬂammatory response and immunoadjuvant therapy. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2019; 23 (3): 76–83. [In Russ.] DOI: 10.21688/1681-3472-2019-3-76-83</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Huang X., Venet F., Wang Y.L., Lepape A., Yuan Z., Chen Y., Swan R., Kherouf H., Monneret G., Chung C.S., Ayala A. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inﬂammatory response to sepsis. Proc Natl Acad Sci USA. 2009; 106 (15): 6303–8. PMID: 19332785. DOI: 10.1073/pnas.0809422106</mixed-citation><mixed-citation xml:lang="en">Huang X., Venet F., Wang Y.L., Lepape A., Yuan Z., Chen Y., Swan R., Kherouf H., Monneret G., Chung C.S., Ayala A. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inﬂammatory response to sepsis. Proc Natl Acad Sci USA. 2009; 106 (15): 6303–8. PMID: 19332785. DOI: 10.1073/pnas.0809422106</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Qin W., Hu L., Zhang X., Jiang S., Li J., Zhang Z., Wang X. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Front Immunol. 2019; 10: 2298. DOI: 10.3389/ﬁmmu.2019.02298. PMID: 31636634; PMCID: PMC6787287</mixed-citation><mixed-citation xml:lang="en">Qin W., Hu L., Zhang X., Jiang S., Li J., Zhang Z., Wang X. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. Front Immunol. 2019; 10: 2298. DOI: 10.3389/ﬁmmu.2019.02298. PMID: 31636634; PMCID: PMC6787287</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jubel J.M., Barbati Z.R., Burger C., Wirtz D.C., Schildberg F.A. The Role of PD-1 in Acute and Chronic Infection. Front Immunol. 2020; 11: 487. DOI: 10.3389/ﬁmmu.2020.00487. PMID: 32265932; PMCID: PMC7105608</mixed-citation><mixed-citation xml:lang="en">Jubel J.M., Barbati Z.R., Burger C., Wirtz D.C., Schildberg F.A. The Role of PD-1 in Acute and Chronic Infection. Front Immunol. 2020; 11: 487. DOI: 10.3389/ﬁmmu.2020.00487. PMID: 32265932; PMCID: PMC7105608</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Саяпина М.С. Иммунорегуляторные функции ингибиторов PD1/PD-L1 и развитие к ним резистентности. Злокачественные опухоли. 2017; (2): 94–99. DOI: 10.18027/2224-5057-2017-2-94-99</mixed-citation><mixed-citation xml:lang="en">Sayapina M.S. Immunoregulatory functions of PD-1/PD-L1 inhibitors and development of resistance to them. Malignant tumours. 2017; (2): 94–99. [In Russ.] DOI: 10.18027/2224-5057-2017-2-94-99</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zitvogel L., Kroemer G. Targeting PD-1 / PD-L1 interactions for cancer immunotherapy. OncoImmunology. 2012; 1 (8): 1223–1225. PMID: 23243584 PMCID: PMC3518493 DOI: 10.4161/onci.21335</mixed-citation><mixed-citation xml:lang="en">Zitvogel L., Kroemer G. Targeting PD-1 / PD-L1 interactions for cancer immunotherapy. OncoImmunology. 2012; 1 (8): 1223–1225. PMID: 23243584 PMCID: PMC3518493 DOI: 10.4161/onci.21335</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ключагина Ю.И., Соколова З.А., Барышникова М.А. Роль рецептора PD-1 и его лигандов PD-L1 и PD-L2 в иммунотерапии опухолей. Онкопедиатрия. 2017; 4 (1): 49–55. DOI: 10.15690/onco.v4i1.1684</mixed-citation><mixed-citation xml:lang="en">Klyuchagina Yu.I., Sokolova Z.A., Baryshnikova M.A. Role of PD1 Receptor and its Ligands PD-L1 and PD-L2 in Cancer Immunotherapy. Oncopediatria. 2017; 4 (1): 49–55. [In Russ.]. DOI: 10.15690/onco.v4i1.1684</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wilson J.K., Zhao Y., Singer M., Spencer J., Shankar-Hari M. Lymphocyte subset expression and serum concentrations of PD-1/ PD-L1 in sepsis pilot study. Crit Care. 2018; 22 (1): 95. DOI: 10.1186/s13054-018-2020-2</mixed-citation><mixed-citation xml:lang="en">Wilson J.K., Zhao Y., Singer M., Spencer J., Shankar-Hari M. Lymphocyte subset expression and serum concentrations of PD-1/ PD-L1 in sepsis pilot study. Crit Care. 2018; 22 (1): 95. DOI: 10.1186/s13054-018-2020-2</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yu X., Pan Y., Fei Q., Lin X., Chen Z., Huang H. Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis. Immun Inﬂamm Dis. 2021; 9 (1): 310-318. Epub 2021 Jan 8. DOI: 10.1002/iid3.394. PMID: 33417300; PMCID: PMC7860599</mixed-citation><mixed-citation xml:lang="en">Yu X., Pan Y., Fei Q., Lin X., Chen Z., Huang H. Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis. Immun Inﬂamm Dis. 2021; 9 (1): 310-318. Epub 2021 Jan 8. DOI: 10.1002/iid3.394. PMID: 33417300; PMCID: PMC7860599</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y., Jia Y., Li C., Shao R., Fang Y. Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit. Shock. 2019; 51 (3): 289-297. DOI: 10.1097/SHK.0000000000001171. PMID: 29702526</mixed-citation><mixed-citation xml:lang="en">Zhao Y., Jia Y., Li C., Shao R., Fang Y. Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit. Shock. 2019; 51 (3): 289-297. DOI: 10.1097/SHK.0000000000001171. PMID: 29702526</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Терехов И.В., Хадарцев А.А., Бондарь С.С., Воеводин А.А. Экспрессия toll- и nod-подобных рецепторов, уровень в мононуклеарных клетках цельной крови регуляторных факторов противовирусной защиты и продукция интерферона под влиянием низкоинтенсивного микроволнового излучения частотой 1 ГГц. Вестник новых медицинских технологий. Электронное издание. 2016; 3: 2–22. URL: http://www.medtsu.tula.ru/VNMT/Bulletin/E2016-3/2-22.pdf (дата обращения: 17.09.2016). DOI: 12737/21557</mixed-citation><mixed-citation xml:lang="en">Terekhov I.V., Khadartsev A.A., Bondar S.S., Voevodin A.A. Expression The Toll- And Nod-Like Receptors, The Levels In Mononuclear Cells Whole Blood, Regulatory Factors Of Antiviral Defense And Interferon Production Product Under The Inﬂuence Of Low-Intensity Microwave Radiation With A Frequency Of 1 Ghz. Journal of New Medical Technologies, eEdition. 2016. No. 3. Publication 2-22. [In Russ.] URL: http://www.medtsu.tula.ru/VNMT/Bulletin/E2016-3/2-22.pdf (date accessed: 17.09.2016). DOI: 12737/21557</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wang H., Wei Y., Zeng Y., Qin Y., Xiong B., Qin G., Li J., Hu D., Qiu X., Sooranna S.R., Pinhu L. The association of polymorphisms of TLR4 and CD14 genes with susceptibility to sepsis in a Chinese population. BMC Medical Genetics. 2014; 15: 123. PMID: 25394369 PMCID: PMC4411696 DOI: 10.1186/s12881-014-0123-4</mixed-citation><mixed-citation xml:lang="en">Wang H., Wei Y., Zeng Y., Qin Y., Xiong B., Qin G., Li J., Hu D., Qiu X., Sooranna S.R., Pinhu L. The association of polymorphisms of TLR4 and CD14 genes with susceptibility to sepsis in a Chinese population. BMC Medical Genetics. 2014; 15: 123. PMID: 25394369 PMCID: PMC4411696 DOI: 10.1186/s12881-014-0123-4</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Матвеев В.Б., Киричек А.А., Сафронова В.М., Кокосадзе Н.В., Халмурзаев О.А., Камолов Б.Ш., Любченко Л.Н. Прогностическое значение PD-L1-статуса опухоли у больных метастатическим раком предстательной железы. Онкоурология. 2019; 15 (1): 57–65. DOI: 10.17650/1726-9776-2019-15-1-57-65</mixed-citation><mixed-citation xml:lang="en">Matveev V.B., Kirichek A.A., Safronova V.M., Kokosadze N.V., Khalmurzaev O.A., Kamolov B.Sh., Lyubchenko L.N. Prognostic value of PD-L1 tumor status in patients with metastatic prostate cancer. Onkourologiya=Cancer Urology. 2019; 15 (1): 57–65. [In Russ.]. DOI: 10.17650/1726-9776-2019-15-1-57-65</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., Bricker T.L., Jarman S.D. 2nd, Kreisel D., Krupnick A.S., Srivastava A., Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011; 350: 17–37. DOI: 10.1007/82_2010_116. PMID: 21061197</mixed-citation><mixed-citation xml:lang="en">Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., Bricker T.L., Jarman S.D. 2nd, Kreisel D., Krupnick A.S., Srivastava A., Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011; 350: 17–37. DOI: 10.1007/82_2010_116. PMID: 21061197</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chen J., Chen R., Huang S., Zu B., Zhang S. Atezolizumab alleviates the immunosuppression induced by PD-L1-positive neutrophils and improves the survival of mice during sepsis. Mol Med Rep. 2021; 23 (2): 1. DOI: 10.3892/mmr.2020.11783. Epub 2020 Dec 15. PMID: 33655320; PMCID: PMC7751480</mixed-citation><mixed-citation xml:lang="en">Chen J., Chen R., Huang S., Zu B., Zhang S. Atezolizumab alleviates the immunosuppression induced by PD-L1-positive neutrophils and improves the survival of mice during sepsis. Mol Med Rep. 2021; 23 (2): 1. DOI: 10.3892/mmr.2020.11783. Epub 2020 Dec 15. PMID: 33655320; PMCID: PMC7751480</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Li J., Tang Z., Xie M., Hang C., Yu Y., Li C. Association between elevation of plasma biomarkers and monocyte dysfunction and their combination in predicting sepsis: An observational single-centre cohort study. Innate Immun. 2020; 26 (6): 514–527. DOI: 10.1177/1753425920926602. Epub 2020 May 26. PMID: 32456597; PMCID: PMC7491234</mixed-citation><mixed-citation xml:lang="en">Li J., Tang Z., Xie M., Hang C., Yu Y., Li C. Association between elevation of plasma biomarkers and monocyte dysfunction and their combination in predicting sepsis: An observational single-centre cohort study. Innate Immun. 2020; 26 (6): 514–527. DOI: 10.1177/1753425920926602. Epub 2020 May 26. PMID: 32456597; PMCID: PMC7491234</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shao R., Fang Y., Yu H., Zhao L., Jiang Z., Li C.S. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratiﬁcation and mortality in septic patients: a prospective cohort study. Crit Care. 2016; 20 (1): 124. PMID: 27156867. DOI: 10.1186/s13054-016-1301-x</mixed-citation><mixed-citation xml:lang="en">Shao R., Fang Y., Yu H., Zhao L., Jiang Z., Li C.S. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratiﬁcation and mortality in septic patients: a prospective cohort study. Crit Care. 2016; 20 (1): 124. PMID: 27156867. DOI: 10.1186/s13054-016-1301-x</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tomino A., Tsuda M., Aoki R., Kajita Y., Hashiba M., Terajima T., Kano H., Takeyama N. Increased PD-1 expression and altered T cell repertoire diversity predict mortality in patients with septic shock: a preliminary study. PLoS One. 2017; 12 (1): e0169653. PMID: 28072859. DOI: 10.1371/journal.pone.0169653</mixed-citation><mixed-citation xml:lang="en">Tomino A., Tsuda M., Aoki R., Kajita Y., Hashiba M., Terajima T., Kano H., Takeyama N. Increased PD-1 expression and altered T cell repertoire diversity predict mortality in patients with septic shock: a preliminary study. PLoS One. 2017; 12 (1): e0169653. PMID: 28072859. DOI: 10.1371/journal.pone.0169653</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Swanson P.E., Green J.M., Hotchkiss R.S. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306 (23): 2594–2605. PMID: 22187279. DOI: 10.1001/jama.2011.1829</mixed-citation><mixed-citation xml:lang="en">Swanson P.E., Green J.M., Hotchkiss R.S. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011; 306 (23): 2594–2605. PMID: 22187279. DOI: 10.1001/jama.2011.1829</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Chang K., Svabek C., Vazquez-Guillamet C., Sato B., Rasche D., Wilson S., Robbins P., Ulbrandt N., Suzich J.A., Green J., Patera A.C., Blair W., Krishnan S.,. Hotchkiss R. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014; 18 (1): R3. PMID: 24387680. DOI: 10.1186/cc13176</mixed-citation><mixed-citation xml:lang="en">Chang K., Svabek C., Vazquez-Guillamet C., Sato B., Rasche D., Wilson S., Robbins P., Ulbrandt N., Suzich J.A., Green J., Patera A.C., Blair W., Krishnan S.,. Hotchkiss R. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014; 18 (1): R3. PMID: 24387680. DOI: 10.1186/cc13176</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Huang X., Chen Y., Chung C.S., Yuan Z., Monaghan S.F., Wang F., Ayala A. Identiﬁcation of B7-H1 as a novel mediator of the innate immune/proinﬂammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol. 2014; 192 (3): 1091–1099. PMID: 24379123. DOI: 10.4049/jimmunol.1302252</mixed-citation><mixed-citation xml:lang="en">Huang X., Chen Y., Chung C.S., Yuan Z., Monaghan S.F., Wang F., Ayala A. Identiﬁcation of B7-H1 as a novel mediator of the innate immune/proinﬂammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol. 2014; 192 (3): 1091–1099. PMID: 24379123. DOI: 10.4049/jimmunol.1302252</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/669/original/%D0%98%D0%BD%D1%84%D0%BE%D0%B3%D1%80%D0%B0%D1%84%D0%B8%D0%BA%D0%B0_COVID-19_v10.pdf</mixed-citation><mixed-citation xml:lang="en">Interim guidelines of the Ministry of Health of Russia «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19).» [In Russ.] Https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/669/original/%D0%98%D0%BD%D1%84%D0%BE%D0%B3%D1%80%D0%B0%D1%84%D0%B8%D0%BA%D0%B0_COVID-19_v10.pdf</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Смирнов В.С., Тотолян А.А. Некоторые возможности иммунотерапии при коронавирусной инфекции. Инфекция и иммунитет. 2020; 10 (3): 446–458.</mixed-citation><mixed-citation xml:lang="en">Smirnov V.S., Totolyan A.A. Some possibilities of immunotherapy for coronavirus infection. Infektsiya i immunitet= Russian Journal of Infection and Immunity. 2020; 10 (3): 446–458. [In Russ.]. DOI: 10.15789/2220-7619-SPO-1470</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов Е.Л. Коронавирусная болезнь-2019 (COVID-19): значение ингибиторов IL-6. Пульмонология. 2020; 30 (5): 629–644. DOI: 10.18093/0869-0189-2020-30-5-629-644</mixed-citation><mixed-citation xml:lang="en">Nasonov E.L. Coronavirus Disease 2019 (COVID-19): The Importance of IL-6 Inhibitors. Pul’monologiya. 2020; 30 (5): 629–644 [In Russ.]. DOI: 10.18093/0869-0189-2020-30-5-629-644</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Сташкив В.И., Замятина К.А., Шантаревич М.Ю., Никитина И. В., Кармазановский Г.Г., Ревишвили А.Ш. КТ-семиотика пневмонии у пациентов с COVID-19, получающих терапию тоцилизумабом: обзор зарубежной литературы. Медицинская визуализация. 2020; 24 (2): 96–97. DOI: 10.24835/1607-0763-2020-2-96-97</mixed-citation><mixed-citation xml:lang="en">Stashkiv V.I., Zamyatina K.A., Shantarevich M.Yu., Nikitina I.V., Kаrmаzаnovsky G.G., Revishvili A.S. CT ﬁndings in patients with COVID-19 pneumonia after treatment with tocilizumab: foreign literature review. Meditsinskaya vizualizatsiya=Medical Visualization. 2020; 24 (2): 96–97. [In Russ.]. DOI: 10.24835/1607-0763-2020-2-96-97</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Безопасность применения ремдесивира и тоцилизумаба при лечении COVID-19. Безопасность и риск фармакотерапии. 2020; 8 (3): 160–162. DOI: 10.30895/2312-7821-2020-8-3-160-162</mixed-citation><mixed-citation xml:lang="en">Safety of Remdesivir and Tocilizumab in COVID-19 Treatment. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2020; 8 (3): 160–162. [In Russ.]. DOI: 10.30895/2312-7821-2020-8-3-160-162</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Андрусова Н.Н., Колганова М.А., Алешина А.В., Шохин И.Е. PD-L1 как потенциальная мишень в противораковой терапии (обзор). Разработка и регистрация лекарственных средств. 2021; 10 (1): 31–36. DOI: 10.33380/2305-2066-2021-10-1-31-36</mixed-citation><mixed-citation xml:lang="en">Andrusova N.N., Kolganova M.A., Aleshina A.V., Shohin I.E. PD-L1 as a Potential Target in Cancer Therapy (Review). Drug development &amp; registration. 2021; 10 (1): 31–36. [In Russ.] DOI: 10.33380/2305-2066-2021-10-1-31-36</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
